Hexiris Ophthalmics

Accueil
Canada
Est, QC
Hexiris Ophthalmics

Hexiris is developing a new generation of ophthalmic devices designed to simplify glaucoma treatment and expand access to care.

We make Interventional Glaucoma (IG) treatment accessible to more patients worldwide.

10/31/2026

Happy Halloween. Here’s the number worth thinking about in glaucoma.

It’s not the surgery. It’s whether a treatment can become part of a patient’s life and stay there.

Medication adherence and persistence remain major challenges in glaucoma care, with studies showing that many patients struggle to maintain their prescribed therapy over time.

At Hexiris, we’re thinking about what treatment could look like when it is designed around the patient, not just the prescription.

No tricks. Just outflow.

Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598.e1–598.e11. doi:10.1016/j.ajo.2005.04.051

10/23/2026

What feels routine today once seemed impossible. Not so long ago, cataract surgery could mean a hospital stay, days of recovery, and a very different patient experience from what we know today.

Then the procedure evolved and became smaller incisions, phacoemulsification, and foldable lenses. Cataract surgery moved from the inpatient ward to the hospital operating room, then to the ambulatory surgery centre, and eventually into the office.

The evolution was not just about making surgery better. It was about bringing care closer to the patient.

So where does glaucoma surgery go next? Over the next five chapters, we’ll follow this evolution, one step at a time.

10/22/2026

Where should glaucoma surgery happen next? At ESCRS in London, we met with Dr. Arsham Sheybani to talk about the changing role of the ophthalmologist, the access challenges facing patients, and why the office may be the next setting for glaucoma surgery.

His perspective starts with a simple question: what happens when the patient needs treatment, but getting to the operating room is the barrier? Volume up to listen.

10/21/2026

What if the next step in glaucoma surgery is not just how we operate, but where?

In a new article for Glaucoma Today, Hexiris cofounder Dr. Nir Shoham-Hazon, MD, explores the potential of office based intervention and how minimally invasive bleb surgery could expand where glaucoma care takes place.

The article looks at the role of OBi™ Core, designed to bring a filtration procedure to the slit lamp or operating room, and the opportunity to rethink access to interventional glaucoma care.

Read “Novel Approaches to Minimally Invasive Bleb Surgery” in Glaucoma Today: https://glaucomatoday.com/articles/2026-july-aug/novel-approaches-to-minimally-invasive-bleb-surgery

Regulatory status varies by product and jurisdiction. OBi Core holds a Health Canada medical device licence and is FDA registered.

10/14/2026

That’s a wrap on AAO 2026. Four days in New Orleans. Dozens of conversations and a lot of questions from comprehensive ophthalmologists exploring Interventional Glaucoma for the first time.

Thank you to everyone who spend time with us in New Orleans. If you took a two pager home, the conversation continues in Expanding Access.

10/12/2026

Happy Thanksgiving from Hexiris! 🇨🇦

Today, while much of our team is in New Orleans for AAO, we’re taking a moment to think about home, the surgeons who have supported us along the way, and the patients who trusted us first.

From Canada and beyond, we’re grateful for the people who continue to shape what we’re building. Thank you, and happy Thanksgiving to our Canadian community.

10/11/2026

Are you at AAO 2026? Our team is on site and ready for conversations with ophthalmologists about where Interventional Glaucoma is heading and what expanding access to care could look like.

If you’re at AAO. We’d love to meet you.

10/08/2026

What happens when a patient is ready for treatment, but the system is not? For millions of people living with glaucoma, access to care is shaped by more than whether a treatment exists.

Our Founders have experienced this first hand and this is the conversation shaping World Sight Day.

Improving eye health is not only about developing better treatments. It is also about making treatment easier to access for everyone in the world.

10/07/2026

Visiting AAO 2026? You’ll find our team with the OBi™ devices in hand and time set aside for one to one conversations and hands on demonstrations. If you’re a comprehensive ophthalmologist curious about Interventional Glaucoma, come see what it looks like at the slit lamp.

Send us a message and we’ll find a time to connect. See you in New Orleans.

𝘖𝘉𝘪 𝘊𝘰𝘳𝘦 𝘪𝘴 𝘭𝘪𝘤𝘦𝘯𝘴𝘦𝘥 𝘣𝘺 𝘏𝘦𝘢𝘭𝘵𝘩 𝘊𝘢𝘯𝘢𝘥𝘢 . 𝘖𝘉𝘪 𝘎𝘰𝘯, 𝘖𝘉𝘪 𝘚𝘩𝘶𝘯𝘵 𝘢𝘯𝘥 𝘖𝘉𝘪 𝘚𝘱𝘢𝘤𝘦𝘳 𝘭𝘪𝘤𝘦𝘯𝘴𝘪𝘯𝘨 𝘢𝘳𝘦 𝘱𝘦𝘯𝘥𝘪𝘯𝘨 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯.

10/05/2026

Filtration surgery has traditionally meant scheduling time in the operating room. But what if it could happen somewhere else?

OBi™ Core is currently being tested and developed for a minimally invasive, ab externo, transconjunctival bleb procedure designed to create a pathway from the anterior chamber to the subconjunctival space, forming a diffuse posterior bleb. The intended procedure is designed to be performed at the slit lamp under topical anaesthesia, without capital equipment.

This is the thinking behind what we are building at Hexiris: expanding where Interventional Glaucoma can happen and bringing treatment closer to the patient.

See OBi™ Core and learn more about what we are building this week at AAO 2026.

𝘖𝘉𝘪 𝘊𝘰𝘳𝘦 𝘪𝘴 𝘭𝘪𝘤𝘦𝘯𝘴𝘦𝘥 𝘣𝘺 𝘏𝘦𝘢𝘭𝘵𝘩 𝘊𝘢𝘯𝘢𝘥𝘢. 𝘖𝘉𝘪 𝘎𝘰𝘯, 𝘖𝘉𝘪 𝘚𝘩𝘶𝘯𝘵 𝘢𝘯𝘥 𝘖𝘉𝘪 𝘚𝘱𝘢𝘤𝘦𝘳 𝘭𝘪𝘤𝘦𝘯𝘴𝘪𝘯𝘨 𝘢𝘳𝘦 𝘱𝘦𝘯𝘥𝘪𝘯𝘨 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯.

Adresse

5085 Avenue Principale Est
Est, QC
E1A9T8

Site Web

https://hexiris.ca/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Hexiris Ophthalmics publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.